Cargando…
Role of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling
Reperfusion therapy is the optimal therapy for acute myocardial infarction (AMI), but acute inflammatory injury and chronic heart failure (HF) after myocardial ischemia and reperfusion (MI/R) remain the leading cause of death after AMI. Pyroptosis, a newly discovered form of cell death, has been pro...
Autores principales: | Shen, Shichun, Wang, Zhen, Sun, Haozhong, Ma, Likun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790935/ https://www.ncbi.nlm.nih.gov/pubmed/35042840 http://dx.doi.org/10.12659/MSM.934255 |
Ejemplares similares
-
Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in vitro by inhibiting NLRP3 Inflammasome activation
por: Huang, Yaru, et al.
Publicado: (2021) -
NLRP3 Inflammasome Activation-Mediated Pyroptosis Aggravates Myocardial Ischemia/Reperfusion Injury in Diabetic Rats
por: Qiu, Zhen, et al.
Publicado: (2017) -
Correction to: Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in vitro by inhibiting NLRP3 Inflammasome activation
por: Huang, Yaru, et al.
Publicado: (2021) -
The Interplay between Autophagy and NLRP3 Inflammasome in Ischemia/Reperfusion Injury
por: Lv, Shuangyu, et al.
Publicado: (2021) -
Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway
por: Zhang, Jing, et al.
Publicado: (2020)